Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : CURIUM US LLC
Deal Size : Undisclosed
Deal Type : Acquisition
Curium Completes Monrol Acquisition To Expand Lutetium-177 Capacity
Details : The acquisition enhances Curium’s manufacturing of Lutetium-177 to meet the growing demand for isotope around the world. Curium’s Lu-177 (Lutetium-177 PSMA-I&T) is being evaluated for Prostate Cancer.
Product Name : Curium Lu-177
Product Type : Radiolabelled Compounds
Upfront Cash : Undisclosed
March 28, 2025
Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : CURIUM US LLC
Deal Size : Undisclosed
Deal Type : Acquisition